Investors shelved their hopes for a pioneering cancer blood test after Illumina‘s $8 billion acquisition ... small real-world study to validate its panel of DNA and protein biomarkers.

chief commercial officer of Illumina. “We are committed to partnering with industry leaders like Bayer and Lilly to advance cancer diagnostics and help broaden access to precision oncology for more ...

IBM Watson Health's Watson for Genomics platform is to help inform cancer treatment ... to data from Illumina's TruSight Tumor 170 platform - a next generation sequencing gene panel that provides ...

Illumina is an applied genomics technology company ... in a patient’s genome for possible predisposition to cancers. Cancer is a disease in the genome, but where do you start when it is peppered ...